The United Kingdom’s Human Milk Oligosaccharides (HMO) market is experiencing rapid expansion, projected to reach USD 10 million (≈ GBP 8 million) by 2035, up from USD 4.6 million (≈ GBP 3.7 million) in 2025, registering a strong 8.1% CAGR during 2025–2035. The market’s upward trajectory is being driven by scientific advances, growing consumer awareness, and the rising preference for infant nutrition products that mimic the benefits of human breast milk.
Key Market Insights at a Glance
- UK HMO market value (2025): USD 4.6 million
- Forecasted market size (2035): USD 10 million (≈ GBP 8 million)
- Anticipated CAGR (2025–2035): 8.1%
- The global HMO market is expected to rise from USD 101 million in 2025 to USD 192 million by 2035, growing at a CAGR of around 6.6%.
- Europe, including the UK, accounted for nearly 78% of global HMO consumption in 2023.
Regional Value: UK’s Strategic Edge
The UK represents a significant share of the European HMO market—approximately 15% in 2023—solidifying its position as a regional innovation hub. Demand is fueled by increasing adoption of premium infant formula products designed to replicate the natural nutritional profile of human breast milk. The UK’s well-structured regulatory landscape and established supply chain infrastructure are key enablers supporting domestic production and imports.
Moreover, the UK’s growing adult and functional nutrition sectors are unlocking new potential for HMO applications, particularly in gut health, immune support, and cognitive function. The country’s investment in biotechnology and synthetic fermentation is further optimizing cost structures, positioning the UK as a critical growth node in the broader European landscape.
Segment Overview
The market is segmented by product type—fucosylated HMOs (2’-FL, 3-FL), sialylated HMOs, and neutral non-fucosylated HMOs—and by end use, including infant formula, functional foods, dietary supplements, and adult nutrition.
Infant formula continues to dominate the UK market, accounting for nearly two-thirds of total HMO consumption, driven by parental demand for formulations that closely resemble natural breast milk. Meanwhile, functional-food and dietary-supplement applications are witnessing increasing traction as manufacturers explore HMOs’ benefits for gut and immune health in adults.
Regional Overview
Several factors are propelling HMO growth across the UK:
- Rising awareness of HMOs’ role in immunity and digestion.
- Government and regulatory approval enabling wider use of HMOs in food and nutrition products.
- Advances in fermentation and synthetic biology that reduce production costs and improve scalability.
Although challenges persist—such as the high cost of fermentation, formulation stability, and compliance hurdles—the UK remains well-positioned to lead European innovation in the sector.
Competitive Landscape
Prominent companies shaping the UK HMO landscape include:
Abbott Laboratories, FrieslandCampina Ingredients, DuPont Nutrition & Biosciences, BASF SE, Chr. Hansen Holding A/S, and Nestlé S.A.
These players are investing heavily in R&D, strategic alliances, and biotechnological innovations to expand HMO production capacity. Many are focusing on high-purity, sustainable fermentation methods to meet the UK’s clean-label and sustainability expectations.
Market Outlook: Powering the Next Decade
The UK HMO market outlook remains positive, underpinned by three core trends:
- Infant Nutrition Innovation: Continued product launches replicating human milk composition are making HMOs a staple in premium infant formulas.
- Technological Scale-Up: Synthetic and microbial fermentation are driving down costs, accelerating the integration of HMOs into mass-market nutrition.
- Functional Nutrition Expansion: HMOs are being recognized for their prebiotic benefits, opening new opportunities in functional foods and adult supplements.
With consistent R&D funding and growing consumer trust, the market is expected to sustain strong growth momentum through 2035.
Key Players of the Sustainable HMO Industry
Sustainability is emerging as a competitive differentiator. Major players are adopting bio-based production, renewable raw materials, and low-carbon processes to align with environmental commitments and consumer preferences. The UK’s advanced biotechnology ecosystem supports this transition, helping manufacturers reduce both environmental impact and cost per unit of HMO output.
Recent Strategic Developments
- Strategic partnerships between HMO producers and UK-based infant formula manufacturers to co-develop localized formulations.
- Expanded investment in fermentation facilities to meet domestic and European demand.
- Regulatory milestones enabling broader inclusion of HMOs in dietary supplements and functional foods.
- Continuous research initiatives validating HMOs’ efficacy in immune support and gut microbiota modulation.
To access the complete data tables and in-depth insights, request a sample report here: https://www.futuremarketinsights.com/reports/sample/rep-gb-21595
Purchase Full Report for Detailed Insights: https://www.futuremarketinsights.com/reports/united-kingdom-human-milk-oligosaccharides-market
Why FMI: https://www.futuremarketinsights.com/why-fmi
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
